Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Randomized controlled trial comparing palifermin and cryotherapy in reducing oral inflammation in stem cell transplant patients
EF 2014-15
Résumé
Treatment for blood cancer patients can involve high-dose chemotherapy followed by stem cell transplant. Melphalan is a high-dose chemotherapy drug that can cause oral cavity inflammation called oral mucositis (OM). OM increases the risk of life-threatening infections, may cause pain, and can increase the occurrence and length of hospitalization. Current prevention methods include intravenous administration of a drug called palifermin or having patients place ice chips in the mouth. A small number of randomized controlled trials (RCTs) have shown that the intervention, whether palifermin or ice chips, was more effective than the placebo under various conditions. Yet, to date, no RCT has compared palifermin to ice chips directly under equivalent and optimized conditions. This study aims to determine which treatment has greater ability to reduce the incidence and duration of severe OM in melphalan-treated stem cell transplant patients. Fifty patients of this described patient population will be randomized to receive either palifermin (25 patients) or ice chips (25 patients). Palifermin group patients will be administered palifermin intravenously on the 3 days prior to melphalan treatment. Ice chips group patients will place ice chips in the mouth immediately before, during, and after melphalan infusion. Each patient's mouth will be assessed daily based on an oral toxicity scale following intervention until they are OM free. The proportion of patients with severe OM and the duration of severe OM will be compared between groups. Which intervention is more effective in reducing the incidence and duration of OM will be determined. Findings may help improve stem cell transplant patient quality of life and optimize healthcare expenditure.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
331416
Name
Suppiah Roopa
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Randomized controlled trial comparing palifermin and cryotherapy in reducing oral inflammation in stem cell transplant patients
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autologous Stem Cell Transplant; Chemotherapy; Cryotherapy; Hematological Cancer; Melphalan; Oral Mucositis; Palifermin; Quality Of Life; Randomized Controlled Trial
Abstract
Treatment for blood cancer patients can involve high-dose chemotherapy followed by stem cell transplant. Melphalan is a high-dose chemotherapy drug that can cause oral cavity inflammation called oral mucositis (OM). OM increases the risk of life-threatening infections, may cause pain, and can increase the occurrence and length of hospitalization. Current prevention methods include intravenous administration of a drug called palifermin or having patients place ice chips in the mouth. A small number of randomized controlled trials (RCTs) have shown that the intervention, whether palifermin or ice chips, was more effective than the placebo under various conditions. Yet, to date, no RCT has compared palifermin to ice chips directly under equivalent and optimized conditions. This study aims to determine which treatment has greater ability to reduce the incidence and duration of severe OM in melphalan-treated stem cell transplant patients. Fifty patients of this described patient population will be randomized to receive either palifermin (25 patients) or ice chips (25 patients). Palifermin group patients will be administered palifermin intravenously on the 3 days prior to melphalan treatment. Ice chips group patients will place ice chips in the mouth immediately before, during, and after melphalan infusion. Each patient's mouth will be assessed daily based on an oral toxicity scale following intervention until they are OM free. The proportion of patients with severe OM and the duration of severe OM will be compared between groups. Which intervention is more effective in reducing the incidence and duration of OM will be determined. Findings may help improve stem cell transplant patient quality of life and optimize healthcare expenditure.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Suppiah, Roopa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~